Metzger Eric, Yin Na, Wissmann Melanie, Kunowska Natalia, Fischer Kristin, Friedrichs Nicolaus, Patnaik Debasis, Higgins Jonathan M G, Potier Noelle, Scheidtmann Karl-Heinz, Buettner Reinhard, Schüle Roland
Universitäts-Frauenklinik und Zentrale Klinische Forschung, Klinikum der Universität Freiburg, Breisacherstrasse 66, 79106 Freiburg, Germany.
Nat Cell Biol. 2008 Jan;10(1):53-60. doi: 10.1038/ncb1668. Epub 2007 Dec 9.
Posttranslational modifications of histones such as methylation, acetylation and phosphorylation regulate chromatin structure and gene expression. Here we show that protein-kinase-C-related kinase 1 (PRK1) phosphorylates histone H3 at threonine 11 (H3T11) upon ligand-dependent recruitment to androgen receptor target genes. PRK1 is pivotal to androgen receptor function because PRK1 knockdown or inhibition impedes androgen receptor-dependent transcription. Blocking PRK1 function abrogates androgen-induced H3T11 phosphorylation and inhibits androgen-induced demethylation of histone H3. Moreover, serine-5-phosphorylated RNA polymerase II is no longer observed at androgen receptor target promoters. Phosphorylation of H3T11 by PRK1 accelerates demethylation by the Jumonji C (JmjC)-domain-containing protein JMJD2C. Thus, phosphorylation of H3T11 by PRK1 establishes a novel chromatin mark for gene activation, identifying PRK1 as a gatekeeper of androgen receptor-dependent transcription. Importantly, levels of PRK1 and phosphorylated H3T11 correlate with Gleason scores of prostate carcinomas. Finally, inhibition of PRK1 blocks proliferation of androgen receptor-induced tumour cell proliferation, making PRK1 a promising therapeutic target.
组蛋白的翻译后修饰,如甲基化、乙酰化和磷酸化,可调节染色质结构和基因表达。在此我们表明,蛋白激酶C相关激酶1(PRK1)在配体依赖性募集至雄激素受体靶基因时,会使组蛋白H3的苏氨酸11(H3T11)发生磷酸化。PRK1对雄激素受体功能至关重要,因为PRK1基因敲低或抑制会阻碍雄激素受体依赖性转录。阻断PRK1功能可消除雄激素诱导的H3T11磷酸化,并抑制雄激素诱导的组蛋白H3去甲基化。此外,在雄激素受体靶启动子处不再观察到丝氨酸5磷酸化的RNA聚合酶II。PRK1介导的H3T11磷酸化可加速含Jumonji C(JmjC)结构域的蛋白JMJD2C介导的去甲基化。因此,PRK1介导的H3T11磷酸化为基因激活建立了一种新的染色质标记,将PRK1确定为雄激素受体依赖性转录的守门人。重要的是,PRK1和磷酸化H3T11的水平与前列腺癌的Gleason评分相关。最后,抑制PRK1可阻断雄激素受体诱导的肿瘤细胞增殖,使PRK1成为一个有前景的治疗靶点。